Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Fibril formation" patented technology

Protein crosslinks to prevent fibril formation

A method is provided for making a protein blocking assembly that is formed by reversibly linking a therapeutic protein to a crosslinking material. The protein blocking assembly contains a chemical structure, which is formed between the multiple bonds between the protein and the crosslinking material, that prevents the interaction of the protein blocking assembly with a second protein due to steric and / or static interference. Furthermore, administration methodologies of administering the protein blocking assembly to a subject are provided, where the protein is cleaved from the protein blocking assembly during or after administration.
Owner:THE CURATORS OF THE UNIVERSITY OF MISSOURI

Compounds, compositions, and method of use to detect islet amyloid polypeptide (IAPP) and inhibit IAPP, alpha-synuclein and TAU protein aggregation

Compounds comprising a rhodanine scaffold, compositions comprising same, method of using such compounds find compositions to inhibit tubulin-associated unit (tau) protein aggregation or alpha-synuclein (α-syn) protein aggregation in a subject having, or at risk for, tau protein aggregation or α-syn protein aggregation, respectively; and methods of using such compounds and compositions to inhibit islet amyloid polypeptide (LAPP) fibril formation and to detect LAPP fibrils.
Owner:PURDUE RES FOUND +2

Compounds for treatment of diabetes and related conditions

Compounds useful in the treatment or prevention of diabetes and related conditions and in the prevention, inhibition or reversal of amylin-amyloid fiber formation, the prevention of Langerhans island (beta) cell death, the prevention or reversal of the conversion of soluble human amylin to insoluble human amylin, the prevention and inhibition or reversal of cytotoxic amylin fiber formation. The present invention relates to compounds of formula (I): (I).
Owner:AUCKLAND UNISERVICES LTD +1

QBP1 for use in the treatment and / or prevention of diabetes

PCT designated stageWO2026027088A1Metabolism disorderPeptide/protein ingredientsPancreatic isletsFibril formation
The present invention relates to the inhibitory effect of QBP1 on hIAPP amyloid formation disrupting the initial stages of hIAPP fibrillogenesis and mitigating hIAPP- induced islet amyloidosis toxicity. The invention relates to the peptide QBP1, or composition comprising thereof, for use in the treatment and / or prevention of the diabetes, particularly type 2 diabetes.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Amyloid fibril formation method, amyloid fibril formation device, and amyloid fibril analysis system

Provided is a novel amyloid fibril formation method that makes it possible to form amyloid fibrils more easily than in the past. According to the present invention, an amyloid fibril formation method for forming amyloid fibrils from an amyloid fibril formation protein involves allowing a fluid that includes the amyloid fibril formation protein to flow into a fluid tube and forming the amyloid fibrils from the amyloid fibril formation protein by transporting the fluid using a means that gradually compresses the fluid tube in one direction to pressurize and depressurize the fluid and thereby move the fluid through the fluid tube.
Owner:DAICEL CORP +1

A peptide capable of inhibiting bacterial biofilm / fibril formation

PCT designated stageWO2026150432A1BiofilmStaphylococcus aureus
The present invention provides a peptide capable of inhibiting and disintegrating bacterial biofilm / fibril formation. Particularly, the present invention provides a retro inverso peptide which can inhibit the biofilm formation as well as disintegrates the pre-formed biofilm of Staphylococcus aureus.
Owner:TATA INSTITUTE OF FUNDAMENTAL RESEARCH

Amyloid peptide variants

IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.
Owner:LOYOLA MARYMOUNT UNIV +1